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Abstract
The rapidly evolving field of metabolomics aims at a comprehensive measurement of ideally all endogenous metabolites in
a cell or body fluid. It thereby provides a functional readout of the physiological state of the human body. Genetic variants
that associate with changes in the homeostasis of key lipids, carbohydrates, or amino acids are not only expected to display
much larger effect sizes due to their direct involvement in metabolite conversion modification, but should also provide
access to the biochemical context of such variations, in particular when enzyme coding genes are concerned. To test this
hypothesis, we conducted what is, to the best of our knowledge, the first GWA study with metabolomics based on the
quantitative measurement of 363 metabolites in serum of 284 male participants of the KORA study. We found associations
of frequent single nucleotide polymorphisms (SNPs) with considerable differences in the metabolic homeostasis of the
human body, explaining up to 12% of the observed variance. Using ratios of certain metabolite concentrations as a proxy
for enzymatic activity, up to 28% of the variance can be explained (p-values 10216 to 10221). We identified four genetic
variants in genes coding for enzymes (FADS1, LIPC, SCAD, MCAD) where the corresponding metabolic phenotype
(metabotype) clearly matches the biochemical pathways in which these enzymes are active. Our results suggest that
common genetic polymorphisms induce major differentiations in the metabolic make-up of the human population. This
may lead to a novel approach to personalized health care based on a combination of genotyping and metabolic
characterization. These genetically determined metabotypes may subscribe the risk for a certain medical phenotype, the
response to a given drug treatment, or the reaction to a nutritional intervention or environmental challenge.
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Introduction
Recent genome-wide association (GWA) studies have identified
a number of genetic polymorphisms that convey an increased risk
for developing diabetes, coronary artery disease, rheumatoid
arthritis, and other common diseases [1–4]. However, by only
associating genotypes with clinical outcomes, little can be inferred
on the disease-causing mechanisms themselves. Moreover, the
effect size of genetic associations with clinical phenotypes is often
small. Therefore, large populations need to be screened in order to
obtain sufficient statistical power for the identification of new
disease-causing genetic variants, as recent genome wide associa-
tion studies with up to 18,000 participants have demonstrated [5–
7]. Metabolomics, which is the rapidly evolving field of measuring
all endogenous metabolites in a cell or body fluid [8–16], may
contribute to solving this problem. Biochemical measurements of
particular intermediate phenotypes on a continuous scale can be
expected to provide more details on potentially affected pathways
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and to be more directly related to the etiology of the disease
(Figure 1). It thereby provides a functional readout of the
physiological state of the human body. Genetic variants that
associate with changes in the homeostasis of key lipids,
carbohydrates or amino acids are not only expected to display
much larger effect sizes due to their direct involvement in
metabolite conversion modification, but may also provide access to
the underlying molecular disease-causing mechanisms.
To test this hypothesis, we quantified the concentrations of a
comprehensive set of naturally occurring organic compounds from
different metabolite classes in blood serum samples from
participants of the KORA F3 GWA study [17–19], and tested
all genotyped common genetic polymorphisms for association with
metabolite concentrations as quantitative traits. We show that if
the function of the associated gene is known, then the biochemical
characteristics of the affected metabolites can support this
association and provide information to identify the underlying
biological processes. Furthermore, whenever a pair of metabolites
is related to the direct substrates and products of an enzymatic
conversion, respectively, the ratio between their concentrations
can be used as an approximation of the enzymatic activity. We
thereby show that the variance in the dataset can be drastically
reduced by using these ratios, which increases the power of the
GWA study and reduces the corresponding p-values of association
by several orders of magnitude. Replication of a newly found
association in an independent population is the gold standard of all
GWA studies. By using metabolite concentrations as proxies for
clinical parameters, such as blood cholesterol levels, some of our
associations represent replications of previous associations with
such parameters.
Results
Based on our experience from previous metabolomics studies [20],
we chose a targeted quantitative metabolomics platform based on
electrospray ionization (ESI) tandem mass spectrometry (MS/MS) to
determine the fasting serum concentrations of up to 363 endogenous
metabolites, including nine sugar molecules, seven biogenic amines,
seven prostaglandins, 29 acylcarnitines, 18 amino acids, 85
sphingolipids, and 208 glycerophospholipids (metabolite naming
conventions are defined in the Material and Methods section; a full
list of all measured metabolites is available as supplementary
material). Data for 201 of these metabolites was obtained for more
than 95% of the samples. We conducted a genome-wide association
study with these metabolic traits in a group of 284 randomly selected
population-based male individuals between 55 and 79 years from the
KORA F3 study [18]. Single nucleotide polymorphisms were
determined previously on a genome-wide scale for this population
using the Affymetrix GeneChip Human Mapping 500K Array Set
[17,19]. To avoid false positive effects from associations based on
small numbers, we limited our analysis to SNPs in which at least 5%
of the population is homozygous for the minor allele. The
corresponding minor allele frequencies are .18.2%. The resulting
p-values of association for all metabolites when using an additive
genetic model are presented in Figure 2. After correction for testing
multiple loci and multiple metabolic traits, we estimated a
conservative genome-wide level of significance of at least
1.3361029. None of the associations that we found attained that
level when considering isolated metabolic traits. However, the best
SNPs rs9309413 (p=1.9561029; Table S3) 21 kb upstream of the
PLEK gene and rs1148259 (p=3.0461029; Table S5) in the 39UTR
of ANKRD30A were only slightly above genome-wide significance.
This is notable because, in contrast to most previous GWA studies, in
which association with few and mostly independent phenotypes was
tested, a GWA study with metabolomics tests multiple and
functionally related outcomes. Moreover, we will show in the
following that signals of genome-wide significant levels (p-values
between 10216 and 10221) can be attained when ratios between
metabolite concentrations are used, and that some of our associations
can also be considered as true positives on biological grounds.
A Prototype of a Genetically Determined Metabotype:
FADS1
We started our analysis by considering polymorphisms in
functionally well characterized enzymes that are among the top
ranking association signals in our GWA study (Tables 1 and S1).
SNP rs174548, one of several SNPs that lie in a linkage
disequilibrium block containing the FADS1 gene was strongly
associated (up to p= 4.5261028) with a number of glyceropho-
spholipid concentrations (Figure 3 and Table 2). This SNP
explains up to 10% of the observed variance of certain
glycerophospholipids. The FADS1 gene codes for the fatty acid
delta-5 desaturase, a key enzyme in the metabolism of long-chain
polyunsaturated omega-3 and omega-6 fatty acids (for a schematic
illustration of this pathway see Figure S1). The minor allele variant
of this SNP (MAF 27.5%) results in a reduced efficiency of the fatty
acid delta-5 desaturase reaction, a fact that can be inferred from
the following observations [21,22]: the concentrations of numer-
ous phosphatidylcholines (PC aa C34:4, PC aa C36:4, PC aa
C36:5, PC aa C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:4,
PC aa C40:5; metabolite abbreviations are explained in the
material and methods section), plasmalogen/plasmenogen phos-
phatidylcholines (PC ae C36:4, PC ae C38:4, PC ae C38:5, PC ae
C38:6, PC ae C40:5), and the phosphatidylinositol PI aa C38:4
with four and more double bonds in their polyunsaturated fatty
acid (PUFA) side chains are lowest in individuals that carry the
minor allele of rs174548. In particular, the concentrations of the
direct product of FADS1, arachidonic acid as well as those of its
lyso-phosphatidylcholine derivative (PC a C20:4) are found to be
significantly reduced with increasing copy number of the minor
allele. On the other hand, concentrations of glycerophospholipids
Author Summary
This paper reports what is, to the best of our knowledge,
the first genome-wide association (GWA) study with
metabolic traits as phenotypic traits. By simultaneous
measurements of single nucleotide polymorphisms (SNPs)
and serum concentrations of endogenous organic com-
pounds in a human population, we identify genetically
determined variants in metabolic phenotype (metabotype)
that exhibit large effect sizes. Four of these polymorphisms
are located in genes coding for well-characterized
enzymes of the lipid metabolism. We find that individuals
with different genotypes in these genes have significantly
different metabolic capacities with respect to the synthesis
of some polyunsaturated fatty acids, the beta-oxidation of
short- and medium-chain fatty acids, and the breakdown
of triglycerides. In this approach, the concept of the
‘‘genetically determined metabotype’’ as an intermediate
phenotype is central, as it becomes a measurable quantity
in the framework of GWA studies with metabolomics. The
investigation of the genetically determined metabotypes
in their biochemical context might help to better
understand the pathogenesis of common diseases and
gene–environment interactions. These findings could
result in a step towards personalized health care and
nutrition based on a combination of genotyping and
metabolic characterization.
A Genome-Wide Association Study with Metabolomics
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with three and less double bonds in their PUFA side chains show a
positive association with the FADS1 genotype. These metabolites
include the phosphatidylcholines PC aa C34:2 and PC aa C36:2,
the plasmalogen/plasmenogen phosphatidylcholines PC ae C34:2
and PC ae C36:2, the phosphatidylethanolamines PE aa C34:2
and PE aa C36:2, and the phosphatidylinositol PI aa C36:2. The
negative association of the sphingomyelin concentrations (SM
C22:2, SM C24:2, SM C28:4) can be interpreted as being a result
of a changed homeostatis of phosphatidylcholins, since sphingo-
myelin can be produced from phosphatidylcholine by the action of
the sphingomyelin synthase. Similarly, the negative association of
the lyso-phosphatidylethanolamin PE a C10:0 can be considered a
consequence of the overall changed balance in glyceropho-
spholipid metabolism, since this metabolite can be produced from
different phosphatidylethanolamines by abstraction of an arachi-
donic acid moiety. In summary, we can conclude that the direction
of all those associations can be explained by a modification in the
efficiency of the fatty acid delta-5 desaturase reaction.
Furthermore, an association of this locus with arachidonic acid
and other polyunsaturated fatty acid concentrations has been
reported previously in two independent experiments [23,24]. This
case thus constitutes a full replication of this association in a third
and independent population, which validates our approach.
Ratios of Metabolite Concentrations Increase the Power
of Association
We have previously shown that analyzing ratios of metabolite
concentrations may strongly reduce the variation in the dataset
when a pair of metabolites is closely connected to the direct
substrates and products of a given enzymatic reaction [20]. When
Figure 1. Schematic illustration of the role of intermediate phenotypes (IPs), such as metabolic traits, demonstrated at the
examples of two genes that code for major enzymes of the long-chain fatty acid metabolism (FADS1 and LIPC). We show that new
information on the functional basis of the observed associations can be inferred from the biochemical properties of the affected metabolites.
Moreover, both genes were previously reported to be associated with common clinical phenotypes, FADS1 in an extent which would not attract
immediate attention for follow-up in a genome-wide context. Since several genes and pathways are involved in the development of a clinical
endpoint, the IP focuses on one pathway (e.g., cholesterol or a given metabotype) which is already known to be involved in the clinical endpoint (e.g.
coronary artery disease (CAD)). It is much easier to identify the genes which are associated with the IP since the associations of genetic variation with
the IP is much stronger than with the clinical endpoint. Environmental factors interact at different levels with the IPs and thereby add to the variability
in the system. The closer the IP is related to the genetic polymorphism, the stronger the association is expected to be. In our case the association
reflects enzymatic activity of FADS1 and LIPC which results in very strong effect sizes of the genetically determined metabotype.
doi:10.1371/journal.pgen.1000282.g001
A Genome-Wide Association Study with Metabolomics
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a tested SNP impacts the efficiency of such a metabolic reaction,
using concentration ratios leads to drastically decreased variance,
and, consequentially, strongly decreased p-values of associations.
Such a dependency not only provides rational evidence for a
positive association, but also points to potentially affected
metabolic pathways, as we demonstrate here for the example of
the FADS1 case. We find that by using metabolite concentration
ratios, the p-value of the association with the polymorphism in the
FADS1 gene decreases by up to fourteen orders of magnitude
(Table 3). Eicosatrienoyl-CoA (C20:3) and arachidonyl-CoA
(C20:4) are the direct substrate and product of the delta-5
desaturase reaction, which is catalyzed by FADS1. Synthesis of
these metabolites to a glycerol 3-phosphate, and further addition
of a palmitoyl-moiety (C16:0), followed by a dephosphorylation
step and the addition of a phosphocholin moiety, leads to the
formation of the glycerol-phosphatidylcholins PC aa C36:3 and
PC aa C36:4, respectively (for a schematic view of the
phosphatidylcholine biosynthesis at the example of PC aa C36:4
see Figure S1). PC aa C36:3 and PC aa C36:4 can thus be
considered as modified substrates and products of the delta-5
desaturase reaction. If the catalytic activity (or the protein
abundance) of FADS1 is reduced by a polymorphism in its gene
(or in a regulatory element), more eicosatrienoyl-CoA (C20:3) and
less arachidonyl-CoA (C20:4) is available for the synthesis of those
glycerophospholipids that contain these fatty acids. This translates
for example into increased PC aa C36:3 concentrations and
reduced PC aa C36:4 concentrations. Thus, the ratio between the
concentrations of the product-substrate pairs of the delta-5
desaturase reaction, such as [PC aa C36:4]/[ PC aa C36:3]
(Figure 4A), will be a strong indicator for the efficiency of the
FADS1 reaction. As reported in Table 3, glycerophospholipids
with three double bonds do not associate with the FADS1
polymorphism (p-values ranging from 0.92 to 0.077), whereas
the corresponding glycerophospholipids with four double bonds
generally display strong associations (most p-values ranging from
1023 to 1028). When considering the ratios between concentra-
tions of matched metabolite pairs, the association with the
polymorphism in the FADS1 gene increases by up to fourteen
orders of magnitude (p-values below 10221). This effect is observed
not only for one, but for a number of different glycerophospholipid
species (PC, PE, PI, incl. plasmalogen/plasmenogen phospholip-
ids) which are thus very likely composed of an arachidonyl-moiety
(C20:4) and either a palmitoyl- (C16:0) or a stearoyl-moiety
(C18:0), respectively (except for lyso-phosphatidylcholin PC a
C20:4, which is formed from a single arachinodyl-moiety). The
strongest effect size is observed for phosphatidylcholine diacyl
C36:4 (PC aa C36:4) to phosphatidylcholine diacyl C36:3 (PC aa
C36:3) ratio (p = 2.4610222). These metabolites are major
constituents of the cell membrane [25 and references therein].
Here, 28.6% of the total variance in the population can be
explained by this SNP (Table 3 and Figure 4A). If the molecular
function of FADS1 had not been already known, the association
between the SNP and the different glycerophospholipid concen-
trations per se would have allowed to deduce its enzymatic activity
of inserting a fourth double bond into long-chain fatty acids.
Association with Medical Phenotypes
Having shown that this polymorphism in the FADS1 gene
strongly influences the serum glycerophospholipid homeostasis, we
investigated the effect of this variation on biochemical variables
related to medical outcomes. As glycerophospholipids play a major
role in cholesterol metabolism, we hypothesized that the FADS1
polymorphism should have a detectable effect on the correspond-
ing serum parameters when looking at a sufficiently large
population. This is indeed the case. Two recent GWA studies
with up to 18,000 participants [5,6] report p-values of association
for SNP rs174548 with serum low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol and total
cholesterol levels that range between 1.8961024 and 6.0761025
(Table 1). These associations have not been included into the list of
potential candidates for replication in those studies, as their p-
values taken alone were not sufficiently small in the context of a
‘‘classical’’ GWA study. Our association of SNP rs174548 with
different glycerophospholipids can be viewed as an indirect
replication of the association of FADS1 with HDL, LDL and total
cholesterol levels in an independent population. Furthermore, we
can now hypothesize that the observed change in cholesterol levels
induced by this SNP is functionally related to the availability of
polyunsaturated long-chain fatty acids with four and more double
bonds and its impact on the homeostasis of different glyceropho-
spholipids. This case shows that a combination of a GWA study
using metabolomic phenotypic traits with data from previous
GWA studies can make it possible to identify promising new
candidate SNPs associated to known phenotypes of medical
relevance, and to gain new insight into the functional background
of these associations.
A Second Genetically Determined Metabotype that
Associates with Medical Phenotype: LIPC
We therefore screened in a further step our strongest
associations for overlap with associations in three recent large
GWA studies, including serum lipid parameters well known to be
involved in cardiovascular diseases as well as seven major common
disease phenotypes [5–7]. Following this strategy, we identified a
series of SNPs in which the biochemical properties of the
associated metabolites support the previously reported associations
with their clinical outcomes (Tables 1 and S1; Datasets S1 and S2).
Figure 2. P-values of association assuming an additive genetic
model, superposing the results obtained from all genome-wide
tested metabolic traits. Chromosomal location is indicated by
different colors on the x-axis, negative logarithmic p-values are reported
on the y-axis. The top ranking SNPs together with the closest gene and
the most significant associating metabolite(s) are indicated. A complete
list of all associations with p,1026 is provided in Table S1, together
with significant associations from previous GWA studies with medical
phenotypes. Metabolite abbreviations are explained in the material and
methods section and a full list of all measured metabolites is provided
as supplementary data.
doi:10.1371/journal.pgen.1000282.g002
A Genome-Wide Association Study with Metabolomics
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One example is SNP rs4775041, which is also in the list of our top
ranking associations. This SNP is located in a linkage disequilib-
rium block containing the gene coding for LIPC, a key enzyme of
the long-chain fatty acid metabolism. This polymorphism
associates with the concentrations of numerous glyceropho-
sphatidylcholines, glycerophosphatidylethanolamines and sphin-
gomyelins (up to p= 9.6661028; Figure 3 and Table S2). For
instance, homozygotes carrying the minor allele have on average
70% higher concentrations of the phosphatidylethanolamine
diacyl C38:6 (PE aa C38:6) than homozygotes for the major
allele. The molecular function of LIPC is to break-down
triglycerides to diacyl- and monoacylglycerols and fatty acids,
which makes this association functionally plausible. In previous
GWA studies this locus was reported to be associated with HDL
cholesterol (p = 2.8061029, 3.061025, 2.061023, and 7.061023)
and triglyceride levels (p = 7.3061025) [5,6,17,26].
Our results thus not only replicate the association of LIPC with
HDL cholesterol and triglyceride levels in an independent
population, but, similar to the FADS1 case, they provide new
insights into the underlying biochemical mechanism of this
Table 1. Genetically determined metabotypes with the strongest signal of association.
Gene PLEK PARK2 ANKRD30A FADS1 LIPC
Position relative to gene 21 kb upstream intron 39UTR intron 49 kb upstream
rs number rs9309413 rs992037 rs1148259 (rs1200826) rs174548 rs4775041
Chromosome 2 6 10 11 15
Chromosomal position 68,482,423 161,971,847 37,548,456 61,327,924 56,461,987
Minor allele frequency 45.2% 34.7% 42.2% 27.5% 28.0%
Best metabolic trait Sphingomyelin SM
C14:0
Lysine Sphingomyelin SM(OH,
COOH) C18:2
Phosphatidylcholine
PC aa C36:4
Phosphatidylethanolamine
PE aa C38:6
P-value of best metabolic trait 1.9561029 1.2061027 3.0461029 4.5261028 9.6661028
Explained variance 12.0% 9.5% 11.7% 10.1% 9.7%
Traits in GWAS
HDL cholesterola 0.035 - - 1.8961024 2.8061029
LDL cholesterola - - - - -
Triglyceridesa - - - 0.0014 7.3061025
2 h glucoseb - - - - -
2 h insulinb - - - - -
Apolipoprotein-I, APOA-1b - - 2.4461024 0.032 2.7561024
Apolipoprotein-II, APOA-2b - - 0.033 0.0055 0.0032
Apolipoprotein B, APOBb - - - - -
Total cholesterolb - - 0.043 1.4861024 0.055
Fasting glucoseb - - - - -
Fasting insulinb - - - - -
HDL cholesterolb - - - 0.037 0.0049
fasting insulin, HOMAb - - - - -
Insulinogenic indexb - - - - 0.016
LDL cholesterolb - - 0.058 6.0761025 -
Triglycerides/HDLb 0.010 - - 0.051 0.025
Triglyceridesb - - - 0.028 0.0071
Bipolar disorderc - - - 0.048 0.046
Coronary artery diseasec - - - 0.021 -
Crohn’s diseasec - - - 0.027 -
Hypertensionc - - - - -
Rheumatoid arthritisc 0.031 - - - 0.059
Type 1 diabetes mellitusc - - - - -
Type 2 diabetes mellitusc - - - - 0.061
Reported are the SNP identifier (rs number), chromosome, chromosomal position, the minor allele frequency (MAF), the metabolic trait with the lowest p-value of
association (test against the null-hypothesis of no association), and percentage of the variance explained by the additive genetic model. Association results for
metabolic traits with p,0.05 are provided in Tables 2, S2, S3, S4, and S5. Data for all 363 metabolic traits are available as supporting online data (Datasets S1 and S2). P-
values of association from previous GWA studies for the same SNP (neighboring SNP rs1200826 for ANKRD30A) are reported for the following traits: (a) HDL cholesterol,
LDL cholesterol, triglycerides are from the publication of Willer et al. [6]; (b) 2 h glucose, 2 h insulin, apolipoproteins A-I, A-II, B, total cholesterol, fasting glucose, fasting
insulin, HOMA insulin resistance, insulinogenic index are from the Diabetes Genetics Initiative (DGI) study [5]; (c) bipolar disorder, coronary artery disease, Crohn’s
disease, hypertension, rheumatoid arthritis, type 1 and type 2 diabetes mellitus are from the WTCCC study [7]. Associations with p-values larger than 0.1 are indicated by
a ‘-’.
doi:10.1371/journal.pgen.1000282.t001
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association by identifying the involved lipid metabolites. Here we
find phosphatidylethanolamines as the most strongly affected
metabolites, prompting further research on their role in the
cholesterol pathway. For instance, one may speculate that the
substrate specificity of LIPC is affected by this genetic polymor-
phism. Interestingly, SNP rs4775041 also weakly associates with
type 2 diabetes (p = 0.061), bipolar disorder (p = 0.048) and
rheumatoid arthritis (p = 0.059), and this in a third, independent
population [7]. These associations are not significant on a genome-
wide scale. However, the associations of this polymorphism with
phospholipids reported here, as well as its associations with blood
cholesterol levels in independent studies suggests that this genetic
variant may indeed be causally related to these diseases, albeit
further studies in larger populations will be needed to test this
hypothesis. In any case, this example indicates how metabolic
traits may serve as intermediate phenotypes to identify potential
links between genetic variance and complex diseases (see Figure 1).
Further Examples: PARK2 and PLEK
It is noteworthy that we could identify and validate two
associations (FADS1 and LIPC) with major genetically determined
metabotypes (concentrations of metabolites and concentration
ratios) among the five strongest associations in our GWA study
despite the moderate number of participants in this study. We
attribute this fact to the unexpectedly large effect sizes in
combination with small variances of the genotype-metabotype
associations. As it is evident that a number of the other top ranking
candidate associations provide information relevant for causal
genotype/phenotype associations, we report these results as
supplementary material to serve as a resource for further research
(Table S1 and Datasets S1 and S2). To give some illustrative
examples, a polymorphism in the PARK2 gene (rs992037; also
among the five strongest associations) alters the concentrations of
several amino acids. Some of these amino acids are directly
connected to the urea cycle (Table S6). PARK2 codes for parkin, a
ubiquitin ligase for which a loss-of-function mutation has been
reported to result in Parkinson’s disease [27]. When using ratios
between metabolite concentrations we observed up to three orders
of magnitude smaller p-values (Table S6). This suggests that this
polymorphism impacts some metabolic pathway that involves
glutamate on the one hand and a number of other amino acids
(except lysine) on the other hand. Thus, the metabolic footprint of
this association is that of an amino acid interconversion, which is
supported by the functional role of PARK2 as a ubiquitin ligase in
the protein degradation pathway. Another example for a
biologically plausible association is SNP rs9309413, which lies
21 kb upstream of PLEK. This SNP has the lowest p-value of
association in this study (p = 1.9561029). The PLEK gene codes
Figure 3. Boxplots of the metabolite concentrations of five top ranking associations as a function of genotype. They show the
differentiation of the population that is induced by these genetically determined metabotypes (0 =major allele homozygote, 1 = heterozygote,
2 =minor allele homozygote). Boxes extend from 1st quartile (Q1) to 3
rd quartile (Q3); median is indicated as a horizontal line; whiskers are drawn to
the observation that is closest to, but not more than, a distance of 1.5(Q3-Q1) from the end of the box. Observations that are more distant than this
are shown individually on the plot. The number of individuals in each group is given below the boxes. P-values for these associations are given in
Table 1.
doi:10.1371/journal.pgen.1000282.g003
A Genome-Wide Association Study with Metabolomics
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for pleckstrin, a protein that has been proposed to facilitate
protein/lipid interactions and to affect membrane structure [28].
The polymorphism we report here impacts on a number of
sphingomyelins, which are known to play a major role in
membrane lipid structure (Table S3).
GWA with Concentration Ratios: SCAD and MCAD
Prompted by the strong increase in the association signal in the
FADS1 example by using metabolite concentration ratios, we
tested the ratios of all possible metabolite pairs for association with
any of the SNPs that have a minor allele frequency higher than
Table 2. Associations of rs174548 (FADS1) with metabolic traits.
metabolite mean ncases p-value estimate explained variance
PC aa C36:4 399.41 284 4.52E-08 20.318 10.11%
PC a C20:4* 5.09 284 5.30E-07 20.293 8.58%
PC aa C38:4 209.05 284 4.91E-06 20.268 7.17%
PC ae C36:5* 19.14 284 1.46E-05 20.255 6.48%
SM C22:2 4.94 284 5.93E-05 20.236 5.59%
PC ae C38:4 30.12 284 1.42E-04 20.224 5.03%
PE aa C34:2 2.22 284 1.54E-04 0.223 4.98%
PC ae C38:5 32.72 284 1.80E-04 20.221 4.88%
PC aa C38:5 128.89 284 2.01E-04 20.219 4.81%
PE e (COOH) C16:3* 5.05 284 1.49E-03 0.188 3.53%
PC ae C36:4 35.16 284 1.68E-03 20.186 3.46%
PE a C10:0 4.16 284 2.34E-03 20.180 3.25%
PC aa C34:2 810.00 284 2.68E-03 0.178 3.16%
SM (COOH) C18:3 7.30 284 3.08E-03 20.175 3.07%
PC aa C34:4 3.25 284 3.25E-03 20.174 3.04%
PC aa C36:5 47.53 284 4.65E-03 20.168 2.82%
PC ae C36:2 25.33 284 5.87E-03 0.163 2.67%
PC aa C40:5 27.52 284 6.21E-03 20.162 2.63%
Arachidonic acid 4.33 283 9.04E-03 20.155 2.41%
PC ae C40:5 6.79 284 1.05E-02 20.152 2.31%
PC aa C40:4 9.53 284 1.07E-02 20.151 2.29%
SM (OH) C26:1 12.75 63 1.15E-02 20.317 10.03%
PI aa C36:2* 7.37 284 1.15E-02 0.150 2.25%
SM C24:2 16.82 221 1.20E-02 20.169 2.86%
PI aa C38:4* 27.03 284 1.21E-02 20.149 2.22%
PC aa (OH, COOH) C30:4 342.95 284 1.29E-02 0.148 2.18%
PC ae C34:2 23.44 284 2.28E-02 0.135 1.83%
SM (OH) C24:0 11.80 208 2.94E-02 20.151 2.29%
LYS 215.17 284 3.05E-02 0.129 1.65%
PA aa C20:7 197.36 284 3.20E-02 20.128 1.63%
PE aa C36:2 4.42 284 3.52E-02 0.125 1.57%
PC aa (COOH) C30:3* 10.38 215 4.00E-02 0.141 1.98%
PC ae C38:6 11.67 284 4.40E-02 20.120 1.44%
PC aa C38:6 146.59 284 4.42E-02 20.120 1.43%
C5-DC 0.11 284 4.43E-02 20.120 1.43%
SM (OH,COOH) C6:0 4.79 63 4.64E-02 0.252 6.35%
SM C28:4 5.51 284 4.73E-02 20.118 1.39%
PI a (OH, COOH) C18:2* 3.74 63 4.84E-02 0.250 6.24%
PC aa C36:2 412.59 284 4.92E-02 0.117 1.37%
Metabolites associated (p,0.05) with genotype rs174548 (FADS1) in the additive genetic model; in cases where alternative assignments of the metabolites are possible,
these are indicated by a ‘*’. Full annotations can be found in the supporting online data files. Reported are the mean concentrations (mM), standard deviation, the
number of cases for which metabolite concentrations were obtained (ncases), the p-value of the association, the regression coefficient using an additive genetic model
(estimate), and the measure of the observed variance that can be explained by the additive genetic model.
doi:10.1371/journal.pgen.1000282.t002
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Figure 4. Boxplots of the strongest associations of metabolite concentration ratios with polymorphisms in the FADS1 (A;
p=2.4610222), SCAD (B; p=9.3610217), and MCAD (C; p=7.6610217) genes (see legend to Figure 3 for details). The metabolic
efficiencies of the reactions that are catalyzed by these three enzymes differ considerably between individuals of different genotype.
doi:10.1371/journal.pgen.1000282.g004
Table 3. Associations of rs174548 (FADS1) with concentrations and ratios between the concentrations of matching pairs of
glycerophospholipid species.
enumerator denominator mean ncases p-value estimate explained variance
Single metabolites (four double bonds)
PC a C20:4* 1 5.094 284 5.361027 20.293 8.58%
PC aa C34:4 1 3.249 284 3.361023 20.174 3.04%
PC aa C36:4 1 399.407 284 4.561028 20.318 10.11%
PC aa C38:4 1 209.050 284 4.961026 20.268 7.17%
PC ae C36:4 1 35.160 284 1.761023 20.186 3.46%
PC ae C38:4 1 30.117 284 1.461024 20.224 5.03%
PE aa C38:4 1 5.357 284 0.13 20.090 0.81%
PI aa C38:4* 1 27.025 284 0.012 20.149 2.22%
Single metabolites (three double bonds)
PC a C20:3* 1 2.461 208 0.86 20.013 0.02%
PC aa C34:3 1 30.751 284 0.21 0.075 0.56%
PC aa C36:3 1 250.496 284 0.56 0.035 0.12%
PC aa C38:3 1 123.002 284 0.66 20.027 0.07%
PC ae C36:3 1 19.697 284 0.17 0.081 0.66%
PC ae C38:3 1 10.641 284 0.74 0.020 0.04%
PE aa C38:3 1 1.623 132 0.92 20.009 0.01%
PI aa C38:3* 1 7.791 221 0.077 0.120 1.43%
Ratios between metabolite concentrations
PC a C20:4* PC a C20:3* 2.224 208 2.961028 20.374 13.98%
PC aa C34:4 PC aa C34:3 0.107 284 4.261027 20.295 8.72%
PC aa C36:4 PC aa C36:3 1.613 284 2.4610222 20.535 28.62%
PC aa C38:4 PC aa C38:3 1.708 284 2.1610217 20.476 22.66%
PC ae C36:4 PC ae C36:3 1.832 284 7.361028 20.313 9.81%
PC ae C38:4 PC ae C38:3 2.888 284 9.761029 20.333 11.07%
PE aa C38:4 PE aa C38:3 3.693 132 0.013 20.216 4.64%
PI aa C38:4* PI aa C38:3* 3.582 221 1.561028 20.370 13.69%
Association of SNP rs174548 (FADS1) with concentrations and ratios between the concentrations of matching pairs of glycerophospholipid species with three-
(denominator) and four-fold (enumerator) unsaturated carbon bonds in their fatty acid side chains; in cases where alternative assignments of the metabolites are
possible, these are indicated by a ‘*’; reported are the mean (mM), the number of cases for which metabolite concentrations were obtained (ncases), the p-value of the
association, the regression coefficient using an additive genetic model (estimate), and the proportion of the observed variance that can be explained by including the
genetic polymorphism in the additive genetic model.
doi:10.1371/journal.pgen.1000282.t003
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20%. We identified two new loci that are comparable to the
FADS1 example in their strength of association and also in terms
of the metabolic traits matching the genes’ function. The first
polymorphism is located in the gene coding for the short-chain
acyl-Coenzyme A dehydrogenase (SCAD; e.g. intronic SNP
rs2014355, minor allele frequency 25.1%), located on chromo-
some 12, and the second lies in the gene coding for the medium-
chain acyl-Coenzyme A dehydrogenase (MCAD; e.g. intronic
SNP rs11161510, minor allele frequency 31.2%) on chromosome
1. Coincidentally, both genes code for enzymes that initiate the
beta-oxidation of fatty acids, but they differ in the preference for
their chain lengths. The metabolite pair that associates most
strongly with rs2014355 of SCAD is the ratio between the short-
chain acylcarnitines C3 and C4 (p= 9.3610217, explained
variance 21.8%, Figure 4B) while the pair that associates most
strongly with rs11161510 of MCAD is the ratio between the
medium-chain acylcarnitines C12 and C8 (p= 7.6610217,
explained variance 21.9%, Figure 4C). Fatty acids are bound to
free carnitine for transport and beta-oxidation into the mitochon-
dria. Similar to our argumentation in the FADS1 example, we can
therefore consider the short-chain acylcarnitines as indirect
substrates and products of SCAD and the medium-chain
acylcarnitines as indirect substrates of MCAD, which matches
the biochemical function of these enzymes. From the direction of
the effect of these polymorphisms (higher concentrations of the
longer chain fatty acids ( = substrates) when compared to the
smaller chain fatty acids ( = products) implies a reduced dehydro-
genase activity) we can further deduce that in both cases minor
allele homozygotes have the lowest enzymatic turnover for these
reactions.
Discussion
Our data support the idea that frequent genetically determined
metabotypes play a role as discriminating cofactors in the etiology
of common multi-factorial diseases. In interactions with environ-
mental factors such as nutrition or life style, these metabotypes
may influence the susceptibility of an individual for certain
phenotypes. As an example, there is growing evidence (which has
yet to be replicated) for a link between the long-chain
polyunsaturated fatty acid metabolism and attention deficit/
hyperactivity syndrome (ADHS). An association of the same
polymorphism in the FADS1 gene that we identified here
(rs174548) has recently been reported to be associated with
ADHS [29]. Genetic variation in the FADS gene cluster has also
been shown to moderate the association between breastfeeding
and intelligence quotient (IQ), by influencing the ability to
metabolize certain fatty acids that are uniquely available in breast
milk [30]. Such effects may possibly be explained by changes in
the membrane fluidity of neuronal cells, which depends on the
degree of membrane fatty acid saturation, and consequentially
impacts the mobility of membrane-bound neuroreceptors.
The differentiation of the population into individuals with
different levels of four-fold and higher-fold unsaturated fatty acids,
as induced by the FADS1 polymorphism, is thus a prototype of a
genetically determined metabotype. LIPC, similar to the case of
FADS1, corresponds to a second prototypic example of a genetically
determined human metabotype. LIPC is indeed a factor related to
modifications in HDL cholesterol levels, and thereby a cofactor in
the etiology of HDL-related diseases, albeit a direct association to
such diseases still requires confirmation. Our results clearly
demonstrate that a GWA study with metabolomic phenotypes
provides a more functional approach to the study of human genetic
variation, increases the power of such studies, and allows for the
identification or confirmation of new associations from previous
GWA studies with clinical parameters as phenotypic traits.
Of particular interest for future research are the two
polymorphisms in the SCAD and MCAD genes. Major deficien-
cies in the corresponding enzymes are known to be associated with
severe systemic disorders and with clinical symptoms such as
hypoketotic hypoglycemia, lethargy, encephalopathy, and seizures.
Such deficiencies are nowadays systematically identified by
neonatal screening programs [31 and references therein]. In
contrast, the genetic variants that we report here show a relatively
moderate phenotypic expression, but are very frequent in the
population (minor allele frequencies .25%). One may speculate
that individuals that are homozygous for at least one of the minor
alleles of the SCAD or MCAD polymorphisms are likely to show
signs of impaired beta-oxidation. One would then expect that, for
instance in situations of prolonged starvation or physical activity,
these individuals may become more readily hypoglycemic and
may display the corresponding symptoms, such as tiredness, loss of
alertness, headache, and memory problems. It would therefore be
promising to search for associations between the SCAD/MCAD
polymorphisms and phenotypes that are related to impaired beta-
oxidation, possibly in the context of diabetes.
The identification of genetic variants that alter the homeostasis
of key metabolites in the human body will eventually lead to a
functional understanding of the genetics of complex diseases. To
achieve this goal, identifying the major genetically determined
metabotypes is mandatory. The current rapid development in the
field of metabolomics promises future access to larger metabolite
panels, larger population sizes, and metabolomics experiments
under different physiological conditions and in different body
fluids. This will allow for a more detailed probing of the human
metabolic network and its associated genetic variants. We argue
that progress towards individualized medication lies in a
combination of genotyping and metabotyping, based on evidence
provided in part by GWA studies combined with metabolomics
like the one presented here. We conclude that metabolomics
delivers its promise of providing access to functionally relevant
endpoints in the framework of GWA studies, and thereby opens
new avenues for a functional investigation of the role of gene-
environment interactions in the etiology of complex diseases.
Material and Methods
Study Population
This study is based on a previously reported genotyping effort
[17,19] whereof we report the essentials here. We recruited the
study population for the genome-wide association study from the
KORA S3 survey that is a population-based sample from the
general population. The dataset comprises individuals aged 25–74
years resident in the region of Augsburg, Southern Germany,
examined in 1994–1995. The standardized examinations applied
have been described in detail elsewhere [18 and references
therein]. We selected 1,644 subjects, who participated in a follow-
up examination of S3 (F3 500K), comprising individuals who, at
that time, were aged 35–79 years. With regard to possible effects
from population stratification it should be noted that previous
work with the KORA F3 500K dataset excluded population
stratification as the origin of an observed association with uric acid
on the basis of comparison with two other studies [19]. Moreover,
possible population stratification in KORA F3 500K was also
excluded based on an EIGENSOFT analysis performed in an
earlier independent report [32]. Also, recent experimental
assessment has found little population stratification to exist within
and across Germany [33].
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Genotyping
Genotyping for KORA F3 500K was done using the Affymetrix
500K Array Set, consisting of two chips (Sty I and Nsp I).
Hybridization of genomic DNA was done in accordance with the
manufacturer’s standard recommendations. Genotypes were
determined using the BRLMM clustering algorithm (http:
//www.affymetrix.com/support/technical/whitepapers/brlmm_
whitepaper.pdf). The genotypes were determined in batches of at
least 400 chips. For quality control purposes, we applied a
positive and a negative control DNA every 48 samples. The
overall genotyping efficiency of the GWA was 98.26%. Before
statistical analysis, we performed filtering of both conspicuous
chips and SNPs based on quality measures to ensure robustness of
association analysis. On chip level only subjects with overall
genotyping efficiencies of at least 93% for both chips and at most
one discordant call for 50 SNPs situated on both chips were
included. In addition the called gender has to agree with the
gender in the KORA study database. On SNP level from a total
of 500,568 SNPs, we excluded for the purpose of this study all
SNPs on chromosome6leaving 490,032 autosomal SNPs for the
GWA screening step. From these 187,454 SNPs (38.25%) passed
all subsequent filter criteria, and were selected for the association
analyses presented in this paper. Criteria leading to exclusion
were genotyping efficiency ,95% (N= 49,325) and genotype
frequency of the minor genotype ,5% (N= 252,405). An exact
Fisher test was used to detect deviations from Hardy Weinberg
Equilibrium, and we excluded all SNPs with p-values below 1026
(N = 848 after passing the other criteria).
Sampling
From the 1644 participants genotyped in the KORA F3 500K
study population, 284 males (55–79 years) were selected at random
for metabolic characterization. Blood samples for metabolic analysis
were collected during 2006. To avoid variation due to circadian
rhythm, blood was drawn in the morning between 8 and 10 am after
a period of overnight fasting. Material was immediately horizontal
shaken (10 min), followed by 40 min resting at 4uC to obtain
complete coagulation. The material was then centrifuged (2000 g;
4uC). Serum was aliquoted and kept for 2–4 hours at 4uC, after
which it was deep frozen to 280uC until sampling.
Metabolite Measurements
Targeted metabolite profiling by electrospray ionization (ESI)
tandem mass spectrometry (MS/MS) was performed on a fee-for-
service basis on a quantitative metabolomics platform at Biocrates
Life Sciences AG, Austria. The company had no access to genotype
or phenotype information that would have permitted any data pre-
filtering other than objective quality control for measurement
errors based on internal controls and duplicates. All metabolomics
data was used as received from Biocrates. We did not apply any
data correction, nor were any data points removed. The
experimental metabolomics measurement technique is described
in detail by patent US 2007/0004044 (accessible online at http://
www.freepatentsonline.com/20070004044.html). A summary of
the method can be found in [34–36] and a comprehensive
overview of the field and the related technologies is given in the
review paper by Wenk [10]. Briefly, a targeted profiling scheme is
used to quantitatively screen for known small molecule metabolites
using multiple reaction monitoring, neutral loss and precursor ion
scans. Quantification of the metabolites of the biological sample is
achieved by reference to appropriate internal standards. The
method has been proven to be in conformance with 21CFR (Code
of Federal Regulations) Part 11, which implies proof of
reproducibility within a given error range. It has been applied in
different academic and industrial applications [20]. Concentra-
tions of all analyzed metabolites are reported in mM (except for
prostaglandin concentrations which are reported in nM units in
the supplementary data files).
Metabolite Panel
In total, 363 different metabolites were detected. The metabo-
lomics dataset contains 18 amino acids, nine reducing mono-, di-
and oligosaccharides (abbreviated as Hn for n-hexose, dH for
desoxyhexose, UA for uronic acid, HNAc for N-acetylglucosamine,
P for Pentose, NANA for N-acetylneuraminic-acid), seven biogenic
amines, five prostaglandins, arachidonic acid (AA), docosahexae-
noic acid (DHA), free carnitine (C0), 28 acylcarnitines (Cx:y),
hydroxylacylcarnitines (C(OH)x:y), and dicarboxylacylcarnitines
(Cx:y-DC), 85 ceramides (Cer), glucosylceramides (GlcCer), differ-
ent sphingomyelins (SMx:y) and sphingomyelin-derivatives, such as
N-hydroxyldicarboacyloylsphingosyl-phosphocholine (SM(OH,-
COOH)x:y) and N-hydroxylacyloylsphingosyl-phosphocholine
(SM(OH)x:y). In addition, 208 phospholipids were detected,
including different glycero-phosphatidic acids (PA), glycero-phos-
phatidylcholines (PC), glycero-phosphatidylethanolamines (PE),
phosphatidylglycerols (PG), glycero-phosphatidylinositols (PI), gly-
cero-phosphatidylinositol-bisphosphates (PIP2), and glycero-phos-
phatidylserines (PS). Glycerophospholipids are further differentiated
with respect to the presence of ester (a) and ether (e) bonds in the
glycerol moiety, where two letters (aa=diacyl, ae=acyl-alkyl,
ee=dialkyl) denote that two glycerol positions are bound to a fatty
acid residue, while a single letter (a=acyl or e=alkyl) indicates the
presence of a single fatty acid residue. Lipid side chain composition
is abbreviated as Cx:y, where x denotes the number of carbons in the
side chain and y the number of double bonds. E.g. ‘‘PC ae C33:1’’
denotes a plasmalogen/plasmenogen phosphatidylcholine with 33
carbons in the two fatty acid side chains and a single double bond in
one of them. The precise position of the double bonds and the
distribution of the carbon atoms in different fatty acid side chains
cannot be determined with this technology. In some cases, the
mapping of metabolite names to individual masses can be
ambiguous. For example, stereo-chemical differences are not always
discernible, neither are isobaric fragments. In such cases, possible
alternative assignments are indicated.
Statistical Analysis
In the statistical analysis only SNPs with a minor allele
homozygote frequency of at least 5% were included in order to
account for the relatively small sample size of the study. The
corresponding smallest minor allele frequency (MAF) in the
analyzed dataset is 18.2%. In a first full genome-wide screen,
metabolites with less than 5% missing values were used (201
metabolite variables). Additive genetic models assuming a trend
per copy of the minor allele were used to specify the dependency of
metabolites on genotype categories in the genome wide association
study. No further adjustment was performed. The linear regression
algorithm implemented in the statistical analysis system R (http://
www.r-project.org/) was used in the genome wide association
study and SPSS for Windows (Version 15.0, Chicago: SPSS Inc.)
was used for statistical analysis on a case-by-case level. It should be
noted that the calculation of p values is based on asymptotic
assumptions, which do not apply down to extremely low levels.
Such p-values should thus be interpreted merely as indicators for
the strength of an association, but not as absolute probabilities. A
conservative estimate of a genome-wide significance level (using
the Bonferroni correction) based on a nominal level of 0.05 is
1.3361029 (0.05 / (201*187,454) ). However, such a small p-value
of an association would only be required to confirm an association
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between a SNP and a single metabolite concentration if all SNPs
and metabolites were acting independently. As explained in the
main text, in the case of a GWA study with metabolomics,
evidence from multiple metabolic traits can be combined into a
multi-factorial ‘‘metabolic story’’, where changes in metabolite
concentrations are interpreted in the context of their position on
the metabolic pathways. To document the complete story all SNPs
that associate with at least one metabolic trait, associations with a
p-value smaller than 1024 are retained for further analysis (2927
SNPs). For these cases, all other metabolic traits that also associate
with the same SNP with a p-value of association smaller than 0.01,
are reported and made available as supporting online data (30641
associations) (Datasets S1 and S2). These have been selected from
a set of 187,454 SNPs. Moreover, the metabolic measures are not
independent, and therefore if by chance one trait associates with
an SNP its correlate would also be expected to associate with that
SNP. For the top ranking associations we then carried out a linear
regression between the associating SNP (additive genetic model),
using all available (max. 363) metabolite concentrations as
quantitative traits. In addition, motivated by our previous
observation [20] that the use of ratios may lead to a strong
reduction in the overall variance and a corresponding improve-
ment in the p-values of association, we computed all possible pairs
of metabolite concentration ratios for those cases and used those
ratios as quantitative traits in a subsequent test. A strong reduction
in p-value indicates that two metabolites may be linked by a
metabolic pathway that is modified by the SNP. A conservative
estimation of the genome-wide significance level (Bonferroni
correction) when testing all metabolite pairs, based on a nominal
level of 0.05, is 6.6610212 (1.3361029/ 201). The results of these
computations are provided as supporting online data for the cases
discussed in this paper. It should be noted that we report there
some particular genetic variants down to p= 0.05.
GWA Data from Other Studies
Genome wide association data (p-values) from three recent
GWA studies was downloaded on 21 February 2008 from http://
www.broad.mit.edu/diabetes/scandinavs/metatraits.html (Broad
Institute [5]) and http://www.sph.umich.edu/csg/abecasis/public/
lipids/ (University of Michigan [6]) and on 14 March 2008 from
http://www.wtccc.org.uk/info/summary_stats.shtml (Wellcome
Trust Case Control Consortium [7]). All p-values of association of
these three GWA studies were combined with our dataset. In the
WTCCC study several methods to compute p-values of association
were used. Here we only use p-values using the additive frequentist
model on the base population (controls and suitable cases merged as
described in [7]). Data points from that study that were flagged as
having bad clustering parameters in the genotype calling were
excluded.
Supporting Information
Figure S1 Schematic view of the role of FADS1 in the synthesis
of phosphatidylcholine. Long-chain poly-unsaturated fatty acids
have to be produced from the essential fatty acid linoleic acids
(C18:2) in the omega-6 fatty acid synthesis pathway (top figure)
and from alpha-linolenic acid (C18:3) in the omega-3 fatty acid
synthesis pathway (not shown). Un- and monosaturated fatty acids
with chain lengths of up to 18 carbons, i.e. palmic acid (C16:0),
stearic acid (C18:0) and oleic acid (C18:1) can be synthesized de
novo in the human body. In the Kennedy pathway, glycerol-
phosphatidylcholins (PC) with different fatty acid side chains are
then produced from two fatty acid moieties (bottom figure). These
are linked to a glycerol 3-phosphate, followed by a dephosphor-
ylation step and the addition of a phosphocholin moiety. A very
good review of the underlying lipid metabolism can be found in
Vance (2001). Figures and pathways shown here were adapted
from the KEGG database at http://www.genome.jp/kegg/
(Kanehisa et al. 2006).
Found at: doi:10.1371/journal.pgen.1000282.s001 (0.53 MB TIF)
Table S1 List of top ranking associations. List of all associations
with a p-value of association smaller than 1026 for at least one of
the tested metabolic traits. Reported are the SNP identifier (rs
number), its chromosome (Chr.) and its chromosomal position
(Position), the minor allele frequency (MAF), and the metabolic
trait with the lowest p-value of association (test against the null-
hypothesis of no association); where an association (p,0.1) of the
same SNP has been reported in one of the recent GWA studies
(WTCCC 2007; Kathiresan et al. 2008; Willer et al. 2008), the p-
value of the strongest association is reported in the comment
column. Abbreviations are explained in the legend to Table 1.
More details and associations up to p,1024 are provided in
supporting online Dataset S1.
Found at: doi:10.1371/journal.pgen.1000282.s002 (0.08 MB
DOC)
Table S2 Associations of rs4775041 (LIPC) with metabolic
traits. Metabolites associated (p,0.05) with genotype rs4775041
(LIPC) in the additive genetic model. In cases where alternative
assignments of the metabolites are possible, these are indicated by
a ‘*’. Full annotations can be found in the supporting online data
files. Reported are the mean concentrations (mM), standard
deviation, the number of cases for which metabolite concentra-
tions were obtained (ncases), the p-value of the association, the
regression coefficient using an additive genetic model (estimate),
and the measure of the observed variance that can be explained by
the additive genetic model.
Found at: doi:10.1371/journal.pgen.1000282.s003 (0.08 MB
DOC)
Table S3 Associations of rs9309413 (PLEK) with metabolic
traits. Metabolites associated (p,0.05) with genotype rs9309413
(PLEK) in the additive genetic model (see Table S2 for legend).
Found at: doi:10.1371/journal.pgen.1000282.s004 (0.09 MB
DOC)
Table S4 Associations of rs1148259 (ANKRD30A) with meta-
bolic traits. Metabolites associated (p,0.05) with genotype
rs1148259 (ANKRD30A) in the additive genetic model (see Table
S2 for legend).
Found at: doi:10.1371/journal.pgen.1000282.s005 (0.09 MB
DOC)
Table S5 Associations of rs992037 (PARK2) with metabolic
traits. Metabolites associated (p,0.05) with genotype rs992037
(PARK2) in the additive genetic model (see Table S2 for legend).
Found at: doi:10.1371/journal.pgen.1000282.s006 (0.08 MB
DOC)
Table S6 Associations of rs992037 (PARK2) with metabolite
concentration ratios. Selected metabolite concentration ratios
associated (p,0.05) with genotype rs992037 (PARK2) in the
additive genetic model (see Table S2 for legend; ncases = 284).
The improvement of the p-value of association when using
metabolite concentration ratios is calculated based on the
following formula: min(p[C_enumerator], p[C_nominator]) /
p[C_enumerator / C_nominator], where C_ is a metabolite
concentration and p[.] the corresponding p-value of association.
Found at: doi:10.1371/journal.pgen.1000282.s007 (0.06 MB
DOC)
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Dataset S1 Association data for all associations with p,1024:
EXCEL worksheet reporting all SNPs (minor allele homozygote
frequency .5%) that associate with at least one metabolic trait
(2927 SNPs); all other metabolic traits that also associate with the
same SNP with a p-value of association smaller than 0.01 are also
reported (30641 associations), together with the corresponding p-
values from previous GWA studies (as described in the
manuscript).
Found at: doi:10.1371/journal.pgen.1000282.s008 (4.48 MB ZIP)
Dataset S2 List of all measured metabolites and their biochem-
ical classification; complete association dataset for the top ranking
cases: EXCEL worksheets comprising the regression results of all
363 metabolites against the genotypes listed in Table 1 in the
additive genetic model (sheets PLEK, ANKRD30A, LIPC,
FADS1, PARK2, SCAD, MCAD) and EXCEL worksheets
comprising the regression results of all 3636363 metabolite
concentration ratios against the genotypes listed in Table 1 in
the additive genetic model, limited to metabolite pairs with p-
values ,1024 when using metabolite concentration ratios (sheets
PLEK_ratios, ANKRD30A_ratios, LIPC_ratios, FADS1_ratios,
PARK2_ratios, SCAD_ratios, MCAD_ratios).
Found at: doi:10.1371/journal.pgen.1000282.s009 (0.40 MB ZIP)
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